The FDA is now approving biomarker-informed therapies on a routine basis, yet there is significant disparity in patient access to molecular profiling that would match cancer patients to these targeted treatments. 


Canexia Health’s Brady Davis recently moderated a panel during the Precision World Medicine Conference (PMWC) in Philadelphia, leading a discussion around providing equitable access to molecular testing within health system settings, from making the business case to reimbursement.


The panelists were:


  • Thuy Phung  | University of South Alabama
  • Michael B Datto M.D., Ph.D.| DUHS Clinical Labs, Duke University Health System, Clinical Laboratories
  • Peter Hulick, M.D. FACMG | Mark R Neaman Ctr. For Personalized Medicine, Northshore University Health System


For key takeaways, read our blog post or watch the full discussion here. 


Recent Resources


August 30, 2022

CGC 2022 Key Takeaways

NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting